1
|
Xiong B and Gerton JL: Regulators of the
cohesin network. Annu Rev Biochem. 79:131–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Brough R, Bajrami I, Vatcheva R, Natrajan
R, Reis-Filho JS, Lord CJ and Ashworth A: APRIN is a cell cycle
specific BRCA2-interacting protein required for genome integrity
and a predictor of outcome after chemotherapy in breast cancer.
EMBO J. 31:1160–1176. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zhang B, Jain S, Song H, Fu M, Heuckeroth
RO, Erlich JM, Jay PY and Milbrandt J: Mice lacking sister
chromatid cohesion protein PDS5B exhibit developmental
abnormalities reminiscent of Cornelia de Lange syndrome.
Development. 134:3191–3201. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Geck P, Szelei J, Jimenez J, Lin TM,
Sonnenschein C and Soto AM: Expression of novel genes linked to the
androgen-induced, proliferative shutoff in prostate cancer cells. J
Steroid Biochem Mol Biol. 63:211–218. 1997. View Article : Google Scholar : PubMed/NCBI
|
5
|
Geck P, Maffini MV, Szelei J, Sonnenschein
C and Soto AM: Androgen-induced proliferative quiescence in
prostate cancer cells: The role of AS3 as its mediator. Proc Natl
Acad Sci USA. 97:10185–10190. 2000. View Article : Google Scholar : PubMed/NCBI
|
6
|
Geck P, Sonnenschein C and Soto AM: The
D13S171 marker, misannotated to BRCA2, links the AS3 gene to
various cancers. Am J Hum Genet. 69:461–463. 2001. View Article : Google Scholar : PubMed/NCBI
|
7
|
Beckmann MW, Picard F, An HX, van Roeyen
CR, Dominik SI, Mosny DS, Schnürch HG, Bender HG and Niederacher D:
Clinical impact of detection of loss of heterozygosity of BRCA1 and
BRCA2 markers in sporadic breast cancer. Br J Cancer. 73:1220–1226.
1996. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gorgoulis VG, Kotsinas A, Zacharatos P,
Mariatos G, Liloglou T, Tsoli E, Kokotas S, Fassoulas C, Field JK
and Kittas C: Association of allelic imbalance at locus D13S171
(BRCA2) and p53 alterations with tumor kinetics and chromosomal
instability (aneuploidy) in nonsmall cell lung carcinoma. Cancer.
89:1933–1945. 2000. View Article : Google Scholar : PubMed/NCBI
|
9
|
Edwards SM, Dunsmuir WD, Gillett CE,
Lakhani SR, Corbishley C, Young M, Kirby RS, Dearnaley DP, Dowe A,
Ardern-Jones A, et al CRC/BPG UK Familial Prostate Cancer Study
Collaborators, : Immunohistochemical expression of BRCA2 protein
and allelic loss at the BRCA2 locus in prostate cancer. Int J
Cancer. 78:1–7. 1998. View Article : Google Scholar : PubMed/NCBI
|
10
|
Harada H, Tanaka H, Shimada Y, Shinoda M,
Imamura M and Ishizaki K: Lymph node metastasis is associated with
allelic loss on chromosome 13q12-13 in esophageal squamous cell
carcinoma. Cancer Res. 59:3724–3729. 1999.PubMed/NCBI
|
11
|
Chen W, Salto-Tellez M, Palanisamy N,
Ganesan K, Hou Q, Tan LK, Sii LH, Ito K, Tan B, Wu J, et al:
Targets of genome copy number reduction in primary breast cancers
identified by integrative genomics. Genes Chromosomes Cancer.
46:288–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kim MS, An CH, Yoo NJ and Lee SH:
Frameshift mutations of chromosome cohesion-related genes SGOL1 and
PDS5B in gastric and colorectal cancers with high microsatellite
instability. Hum Pathol. 44:2234–2240. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ma J, Cui Y, Cao T, Xu H, Shi Y, Xia J,
Tao Y and Wang ZP: PDS5B regulates cell proliferation and motility
via upregulation of Ptch2 in pancreatic cancer cells. Cancer Lett.
460:65–74. 2019. View Article : Google Scholar : PubMed/NCBI
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Chung HJ, Yoon SI, Shin SH, Koh YA, Lee
SJ, Lee YS and Bae S: p53-mediated enhancement of radiosensitivity
by selenophosphate synthetase 1 overexpression. J Cell Physiol.
209:131–141. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Levy DE and Lee CK: What does Stat3 do? J
Clin Invest. 109:1143–1148. 2002. View Article : Google Scholar : PubMed/NCBI
|
17
|
Harada H, Uchida N, Shimada Y, Kumimoto H,
Shinoda M, Imamura M and Ishizaki K: Polymorphism and allelic loss
at the AS3 locus on 13q12-13 in esophageal squamous cell carcinoma.
Int J Oncol. 18:1003–1007. 2001.PubMed/NCBI
|
18
|
Zhang Y, Huang X, Qi J, Yan C, Xu X, Han Y
and Wang M: Correlation of genomic and expression alterations of
AS3 with esophageal squamous cell carcinoma. J Genet Genomics.
35:267–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Reis EM, Ojopi EP, Alberto FL, Rahal P,
Tsukumo F, Mancini UM, Guimarães GS, Thompson GM, Camacho C,
Miracca E, et al Head and Neck Annotation Consortium, : Large-scale
transcriptome analyses reveal new genetic marker candidates of
head, neck, and thyroid cancer. Cancer Res. 65:1693–1699. 2005.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhou X, Kong X, Xu W and Chen J:
Overexpression of APRIN inhibits differentiation and proliferation
and promotes apoptosis in P19 embryonal carcinoma cells. Mol Biol
Rep. 40:491–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
22
|
Yu H and Jove R: The STATs of cancer--new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai
YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating
interleukin-6 level is a prognostic marker for survival in advanced
nonsmall cell lung cancer patients treated with chemotherapy. Int J
Cancer. 132:1977–1985. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Pine SR, Mechanic LE, Enewold L,
Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso
NE and Harris CC: Increased levels of circulating interleukin 6,
interleukin 8, C-reactive protein, and risk of lung cancer. J Natl
Cancer Inst. 103:1112–1122. 2011. View Article : Google Scholar : PubMed/NCBI
|
25
|
Songür N, Kuru B, Kalkan F, Özdilekcan C,
Çakmak H and Hizel N: Serum interleukin-6 levels correlate with
malnutrition and survival in patients with advanced non-small cell
lung cancer. Tumori. 90:196–200. 2004. View Article : Google Scholar : PubMed/NCBI
|
26
|
Xiao W, Hodge DR, Wang L, Yang X, Zhang X
and Farrar WL: Co-operative functions between nuclear factors
NFkappaB and CCAT/enhancer-binding protein-β (C/EBP-β) regulate the
IL-6 promoter in autocrine human prostate cancer cells. Prostate.
61:354–370. 2004. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sehgal PB: Regulation of IL6 gene
expression. Res Immunol. 143:724–734. 1992. View Article : Google Scholar : PubMed/NCBI
|
28
|
Squarize CH, Castilho RM, Sriuranpong V,
Pinto DS Jr and Gutkind JS: Molecular cross-talk between the
NFkappaB and STAT3 signaling pathways in head and neck squamous
cell carcinoma. Neoplasia. 8:733–746. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Yang J, Liao X, Agarwal MK, Barnes L,
Auron PE and Stark GR: Unphosphorylated STAT3 accumulates in
response to IL-6 and activates transcription by binding to
NFkappaB. Genes Dev. 21:1396–1408. 2007. View Article : Google Scholar : PubMed/NCBI
|